Baidu
map

呼吸指南

订阅

MedSci主页 / 所有栏目 / 呼吸指南

2018 ERS/EACTS声明：恶性胸腔积液的管理

2018-07-27 欧洲呼吸学会 Eur Respir J. 2018 Jul 27;52(1).

恶性胸腔积液

恶性胸腔积液是一种常见的病理状态，主要由呼吸科科胸外科医生管理。本文为ERS联合EACTS共识制定的关于恶性胸腔积液的管理声明，主要涉及6个方面的内容，包括胸腔积液的症状管理，肺萎陷的管理，包裹性胸腔积液的管理，预后因素组织学诊断等。

中文标题：

2018 ERS/EACTS声明：恶性胸腔积液的管理

英文标题：

ERS/EACTS statement on the management of malignant pleural effusions.

发布机构：

欧洲呼吸学会

发布日期：

2018-07-27

简要介绍：

恶性胸腔积液是一种常见的病理状态，主要由呼吸科科胸外科医生管理。本文为ERS联合EACTS共识制定的关于恶性胸腔积液的管理声明，主要涉及6个方面的内容，包括胸腔积液的症状管理，肺萎陷的管理，包裹性胸腔积液的管理，预后因素组织学诊断等。 

拓展指南：与胸腔积液相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 ERS/EACTS声明：恶性胸腔积液的管理)] GetToolGuiderByIdResponse(projectId=1, id=f36b11c0016226eb, title=2018 ERS/EACTS声明：恶性胸腔积液的管理, enTitle=ERS/EACTS statement on the management of malignant pleural effusions., guiderFrom=Eur Respir J. 2018 Jul 27;52(1)., authorId=null, author=, summary=恶性胸腔积液是一种常见的病理状态，主要由呼吸科科胸外科医生管理。本文为ERS联合EACTS共识制定的关于恶性胸腔积液的管理声明，主要涉及6个方面的内容，包括胸腔积液的症状管理，肺萎陷的管理，包裹性胸腔积液的管理，预后因素组织学诊断等。 , cover=, journalId=null, articlesId=null, associationId=172, associationName=欧洲呼吸学会, associationIntro=欧洲呼吸学会（ERS）是欧洲专业学会组织，是具有广泛基础的拥有100多个国家的大约一万名成员。内容涵盖了基础科学和临床医学。, copyright=0, guiderPublishedTime=Fri Jul 27 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>恶性胸腔积液是一种常见的病理状态，主要由呼吸科科胸外科医生管理。本文为ERS联合EACTS共识制定的关于恶性胸腔积液的管理声明，主要涉及6个方面的内容，包括胸腔积液的症状管理，肺萎陷的管理，包裹性胸腔积液的管理，预后因素组织学诊断等。 </div> <div><br> </div>拓展指南：<strong>与<font color=red>胸腔积液</font>相关指南：</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=c0b231c00105609a" title="2014 恶性胸腔积液诊断与治疗专家共识" target=_blank>2014 恶性胸腔积液诊断与治疗专家共识</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=bbb101c000e85886" title="2010 BTS 胸膜疾病指南：成人单侧胸腔积液的诊治" target=_blank>2010 BTS 胸膜疾病指南：成人单侧胸腔积液的诊治</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=de9c81c000e857b0" title="2010BTS 英国胸科学会胸膜疾病指南：恶性胸腔积液" target=_blank>2010BTS 英国胸科学会胸膜疾病指南：恶性胸腔积液</a></li> 更多信息请点击：<a href="//m.capotfarm.com/guideline/list.do?q=%E8%83%B8%E8%85%94%E7%A7%AF%E6%B6%B2" target=_blank>有关胸腔积液更多指南</a></ul>, tagList=[TagDto(tagId=31458, tagName=恶性胸腔积液)], categoryList=[CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6636, appHits=363, showAppHits=8, pcHits=4599, showPcHits=2476, likes=111, shares=13, comments=4, approvalStatus=1, publishedTime=Wed Aug 01 21:03:40 CST 2018, publishedTimeString=2018-07-27, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Aug 01 21:03:40 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 16:42:16 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 ERS/EACTS声明：恶性胸腔积液的管理)])
2018 ERS/EACTS声明：恶性胸腔积液的管理
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=345412, encodeId=617d345412c1, content=学习了，谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1e1506062, createdName=nanhaizhihuo2009, createdTime=Mon Sep 17 23:17:22 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336036, encodeId=07e5336036df, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/07/86eb8ff0cc5e04d9b292a27c2970a0be.jpg, createdBy=73691616008, createdName=text, createdTime=Fri Aug 03 14:26:58 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336028, encodeId=c93033602834, content=很赞，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/d95fde48d2044f401185c488baba9736.jpg, createdBy=ac6c78427, createdName=test1797, createdTime=Fri Aug 03 13:58:49 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335602, encodeId=f9ac3356025f, content=不错的文章值得拥有哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Aug 01 22:33:24 CST 2018, time=2018-08-01, status=1, ipAttribution=)]
    2018-09-17 nanhaizhihuo2009

    学习了，谢谢！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=345412, encodeId=617d345412c1, content=学习了，谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1e1506062, createdName=nanhaizhihuo2009, createdTime=Mon Sep 17 23:17:22 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336036, encodeId=07e5336036df, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/07/86eb8ff0cc5e04d9b292a27c2970a0be.jpg, createdBy=73691616008, createdName=text, createdTime=Fri Aug 03 14:26:58 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336028, encodeId=c93033602834, content=很赞，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/d95fde48d2044f401185c488baba9736.jpg, createdBy=ac6c78427, createdName=test1797, createdTime=Fri Aug 03 13:58:49 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335602, encodeId=f9ac3356025f, content=不错的文章值得拥有哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Aug 01 22:33:24 CST 2018, time=2018-08-01, status=1, ipAttribution=)]
    2018-08-03 text

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=345412, encodeId=617d345412c1, content=学习了，谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1e1506062, createdName=nanhaizhihuo2009, createdTime=Mon Sep 17 23:17:22 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336036, encodeId=07e5336036df, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/07/86eb8ff0cc5e04d9b292a27c2970a0be.jpg, createdBy=73691616008, createdName=text, createdTime=Fri Aug 03 14:26:58 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336028, encodeId=c93033602834, content=很赞，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/d95fde48d2044f401185c488baba9736.jpg, createdBy=ac6c78427, createdName=test1797, createdTime=Fri Aug 03 13:58:49 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335602, encodeId=f9ac3356025f, content=不错的文章值得拥有哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Aug 01 22:33:24 CST 2018, time=2018-08-01, status=1, ipAttribution=)]
    2018-08-03 test1797

    很赞，学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=345412, encodeId=617d345412c1, content=学习了，谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1e1506062, createdName=nanhaizhihuo2009, createdTime=Mon Sep 17 23:17:22 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336036, encodeId=07e5336036df, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/07/86eb8ff0cc5e04d9b292a27c2970a0be.jpg, createdBy=73691616008, createdName=text, createdTime=Fri Aug 03 14:26:58 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336028, encodeId=c93033602834, content=很赞，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/d95fde48d2044f401185c488baba9736.jpg, createdBy=ac6c78427, createdName=test1797, createdTime=Fri Aug 03 13:58:49 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335602, encodeId=f9ac3356025f, content=不错的文章值得拥有哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Aug 01 22:33:24 CST 2018, time=2018-08-01, status=1, ipAttribution=)]
    2018-08-01 1e1b8538m79(暂无匿称)

    不错的文章值得拥有哦

    0

相关指南

重组改构人肿瘤坏死因子治疗恶性胸、腹腔积液的临床应用专家共识

中国临床肿瘤学会抗肿瘤药物安全管理专家委员会(ASMC) · 2017-01-30

Baidu
map
Baidu
map
Baidu
map